Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A reappraisal of polymyxin B dosing based on population pharmacokinetic model in patient with renal insufficiency

View ORCID ProfileXuben Yu, Chunhong Zhang, Jingye Pan, Ying Dai, Ziye Zhou, Fan Yang, Ruolan Sun, Yexuan Wang, Yancheng Cao, Changcheng Sheng, View ORCID ProfileZheng Jiao, Guanyang Lin
doi: https://doi.org/10.1101/2020.01.24.20018481
Xuben Yu
1Department of Pharmacy, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xuben Yu
Chunhong Zhang
1Department of Pharmacy, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingye Pan
1Department of Pharmacy, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying Dai
1Department of Pharmacy, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ziye Zhou
1Department of Pharmacy, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fan Yang
3Department of Pharmacy, Wenzhou Medical University, Wenzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruolan Sun
3Department of Pharmacy, Wenzhou Medical University, Wenzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yexuan Wang
3Department of Pharmacy, Wenzhou Medical University, Wenzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yancheng Cao
3Department of Pharmacy, Wenzhou Medical University, Wenzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Changcheng Sheng
4Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheng Jiao
2Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zheng Jiao
  • For correspondence: 13867702133@163.com jiaozhen128@hotmail.com
Guanyang Lin
1Department of Pharmacy, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: 13867702133@163.com jiaozhen128@hotmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Current FDA-approved label recommends polymyxin B dosing should be adjusted according to renal function, despite several studies proved poor correlation between polymyxin B PK and creatinine clearance. The study aims to assess the impact of renal function on polymyxin B metabolism and identify an alternate dosing strategy by population analysis.

Methods Blood samples from adult patients were collected at steady state during routine therapeutic drug monitoring. Nonlinear mixed effects modeling was employed to build a population PK model of polymyxin B. Monte Carlo simulations were performed to design polymyxin B dosing regimens across various renal function.

Results Pharmacokinetic analyses included 112 polymyxin B concentrations at steady state from 32 adult patients aged 37-93 received intravenous polymyxin B (100-200 mg/d). The creatinine clearance in patients was 5.91-244 mL/min. In the final population PK model, CrCL was the significant covariate on CL (typical value, 1.59 L/hr; between-subject variability, 13%). Mean (SD) individual empirical Bayesian estimates of CL was 1.75 (0.43) L/hr. A new dosing strategy combining the PK/PD targets and Monte Carlo simulation indicated that polymyxin B dose reductions improved the probability of achieving optimal exposures in simulated patients with renal insufficiency. For severe infections caused by organisms with MIC of ≥ 2 mg/L, though a high daily dose (e.g. 200mg/day) would possible for bacterial eradication, the risk of nephrotoxicity is significantly increased.

Conclusion A population PK model was established to develop individualized polymyxin B dosage regimens that the dose of polymyxin B should be adjusted according to CrCL.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ChiCTR1900025031

Funding Statement

None

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The Data are available for inquiry

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 28, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A reappraisal of polymyxin B dosing based on population pharmacokinetic model in patient with renal insufficiency
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A reappraisal of polymyxin B dosing based on population pharmacokinetic model in patient with renal insufficiency
Xuben Yu, Chunhong Zhang, Jingye Pan, Ying Dai, Ziye Zhou, Fan Yang, Ruolan Sun, Yexuan Wang, Yancheng Cao, Changcheng Sheng, Zheng Jiao, Guanyang Lin
medRxiv 2020.01.24.20018481; doi: https://doi.org/10.1101/2020.01.24.20018481
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
A reappraisal of polymyxin B dosing based on population pharmacokinetic model in patient with renal insufficiency
Xuben Yu, Chunhong Zhang, Jingye Pan, Ying Dai, Ziye Zhou, Fan Yang, Ruolan Sun, Yexuan Wang, Yancheng Cao, Changcheng Sheng, Zheng Jiao, Guanyang Lin
medRxiv 2020.01.24.20018481; doi: https://doi.org/10.1101/2020.01.24.20018481

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (412)
  • Dentistry and Oral Medicine (69)
  • Dermatology (47)
  • Emergency Medicine (142)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4843)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (674)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (626)
  • Health Policy (318)
  • Health Systems and Quality Improvement (203)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5326)
  • Intensive Care and Critical Care Medicine (328)
  • Medical Education (93)
  • Medical Ethics (25)
  • Nephrology (75)
  • Neurology (685)
  • Nursing (42)
  • Nutrition (114)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (205)
  • Oncology (439)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (89)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (778)
  • Public and Global Health (1810)
  • Radiology and Imaging (323)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)